BACK
|Enrolling,Lipoprotein (a)

Acclaim

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).

More Information

Capital Area Research LLC © Copyright 2024 All rights reserved.
875 Popular Church Rd. Suite 330 Camp Hill, PA - 717.963.8389